Assenagon Asset Management S.A. Sells 7,720 Shares of Danaher Co. (NYSE:DHR)

Assenagon Asset Management S.A. decreased its position in shares of Danaher Co. (NYSE:DHR) by 26.9% in the 3rd quarter, Holdings Channel reports. The firm owned 20,930 shares of the conglomerate’s stock after selling 7,720 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Danaher were worth $5,819,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher in the second quarter valued at approximately $25,000. nVerses Capital LLC acquired a new position in shares of Danaher during the 2nd quarter valued at $25,000. Redmont Wealth Advisors LLC bought a new position in Danaher during the first quarter worth $30,000. MFA Wealth Advisors LLC acquired a new stake in Danaher in the second quarter worth $51,000. Finally, Financial Connections Group Inc. bought a new stake in Danaher in the second quarter valued at $51,000. 79.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Evercore ISI increased their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Barclays cut their price target on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. The Goldman Sachs Group boosted their price objective on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Stephens reiterated an “overweight” rating and issued a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. Finally, Bank of America boosted their price target on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $287.28.

Insider Buying and Selling

In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,052 shares of company stock valued at $5,878,937. 11.10% of the stock is owned by company insiders.

Danaher Stock Performance

DHR stock opened at $242.78 on Wednesday. The business has a 50 day moving average of $268.40 and a 200-day moving average of $260.55. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The firm has a market cap of $179.82 billion, a PE ratio of 41.15, a P/E/G ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the firm earned $2.02 EPS. The firm’s quarterly revenue was up 3.1% on a year-over-year basis. As a group, sell-side analysts expect that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s payout ratio is currently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.